Vol. 1 No. 2 (2025)

ASIDE Gastroenterology Vol. 1, No. 2 (August 1, 2025) brings together practice-focused scholarship across IBD, hepatology, therapeutic endoscopy, and GI oncology. The issue opens with an Editorial on equitable adoption of emerging GI therapies, followed by an original investigation of mycophenolate mofetil use in inflammatory bowel disease and a retrospective analysis of biliary complications among jaundiced patients with alcohol-related hepatitis. Two evidence syntheses address procedural and pediatric care: a systematic review and meta-analysis evaluating sodium alginate and mesna as adjuncts in endoscopic submucosal dissection, and a systematic review assessing the efficacy and safety of tofacitinib in pediatric ulcerative colitis. Rounding out the issue, a systematic review of randomized trials compares tislelizumab plus chemotherapy with placebo plus chemotherapy for advanced gastric or gastroesophageal junction cancer. Collectively, these articles reflect ASIDE’s commitment to rigorous, inclusive research that informs day-to-day clinical decision-making and advances health equity in gastroenterology.